Literature DB >> 11091210

Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia.

M Chilosi1, R Chiarle, M Lestani, F Menestrina, L Montagna, A Ambrosetti, G Prolla, G Pizzolo, C Doglioni, R Piva, M Pagano, G Inghirami.   

Abstract

The molecular basis accounting for the peculiar clinical and biological features of hairy cell leukaemia (HCL) is currently unknown. Deregulation of cell cycle genes plays a significant role in oncogenesis and there is considerable evidence suggesting that Cdk inhibitors (Ckis) function as tumour suppressors. We and others have recently demonstrated low expression of Cki p27 in very aggressive neoplasms and high-grade lymphomas. To investigate whether HCL cases express normal p27 protein, as in other low-grade lymphomas with a low proliferation index, 58 cases of HCL were characterized using a sensitive biotin-streptavidin-immunoperoxidase technique and specific antibodies against p27. All HCL cases showed either no or very weak reactivity, in contrast to other types of low-grade B-cell lymphoma [22 cases of chronic lymphocytic leukaemia (CLL), 12 cases of gastric marginal B-cell lymphoma (MALT), 16 cases of follicular lymphomas and two cases of splenic marginal zone lymphomas]. To investigate the possible mechanism(s) accounting for the low p27 expression observed in hairy cells, multiple approaches were used. According to these molecular studies, low levels of p2 7 are not as a result of (1) increased ubiquitin-mediated degradation, (2) decreased levels of p27 transcription or (3) p27 somatic mutations and/or allelic loss. These findings suggest that low p27 protein expression in HCL may be achieved through post-transcriptional regulation. Finally, our data demonstrate that p27 expression in HCL does not correlate with either cell cycle progression or proliferation index, suggesting that low levels of p27 in hairy cells may be associated with their unique stage of B-cell differentiation and/or the activation of as yet unknown pathways.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11091210     DOI: 10.1046/j.1365-2141.2000.02210.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  BRAF mutations in hairy-cell leukemia.

Authors:  Enrico Tiacci; Vladimir Trifonov; Gianluca Schiavoni; Antony Holmes; Wolfgang Kern; Maria Paola Martelli; Alessandra Pucciarini; Barbara Bigerna; Roberta Pacini; Victoria A Wells; Paolo Sportoletti; Valentina Pettirossi; Roberta Mannucci; Oliver Elliott; Arcangelo Liso; Achille Ambrosetti; Alessandro Pulsoni; Francesco Forconi; Livio Trentin; Gianpietro Semenzato; Giorgio Inghirami; Monia Capponi; Francesco Di Raimondo; Caterina Patti; Luca Arcaini; Pellegrino Musto; Stefano Pileri; Claudia Haferlach; Susanne Schnittger; Giovanni Pizzolo; Robin Foà; Laurent Farinelli; Torsten Haferlach; Laura Pasqualucci; Raul Rabadan; Brunangelo Falini
Journal:  N Engl J Med       Date:  2011-06-11       Impact factor: 91.245

2.  Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation.

Authors:  Carlos le Sage; Remco Nagel; David A Egan; Mariette Schrier; Elly Mesman; Annunziato Mangiola; Corrado Anile; Giulio Maira; Neri Mercatelli; Silvia Anna Ciafrè; Maria Giulia Farace; Reuven Agami
Journal:  EMBO J       Date:  2007-07-12       Impact factor: 11.598

Review 3.  Genomics of Hairy Cell Leukemia.

Authors:  Enrico Tiacci; Valentina Pettirossi; Gianluca Schiavoni; Brunangelo Falini
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

Review 4.  The Genomics of Hairy Cell Leukaemia and Splenic Diffuse Red Pulp Lymphoma.

Authors:  David Oscier; Kostas Stamatopoulos; Amatta Mirandari; Jonathan Strefford
Journal:  Cancers (Basel)       Date:  2022-01-29       Impact factor: 6.639

5.  BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.

Authors:  Valentina Pettirossi; Alessia Santi; Elisa Imperi; Guido Russo; Alessandra Pucciarini; Barbara Bigerna; Gianluca Schiavoni; Elisabetta Fortini; Ariele Spanhol-Rosseto; Paolo Sportoletti; Roberta Mannucci; Maria Paola Martelli; Ludger Klein-Hitpass; Brunangelo Falini; Enrico Tiacci
Journal:  Blood       Date:  2014-12-05       Impact factor: 22.113

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.